Neuromeka

At a glance

Neuromeka filed 99 disclosures in the last 12 months, including 32 insider, 18 5% holder, 2 contract and 1 issuance. The most recent key filing was on Oct 26: A major holder's stake rose from 14.98% to 14.98% (related-party change).

Revenue for 2025 was ₩19B, down 25% on 2024. It made an operating loss of ₩14.9B. Debt was 558% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩5.8B and operating loss of ₩9.6B.

The 2025 annual report lists 149 employees with an average tenure of 2.1 years and average pay of ₩60.4M, #952 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩137M each on average. It paid no cash dividend for 2025. 박종훈 and related parties held 19.92% at year end.

Of 1 recent 5%+ holder report, 0 raised and 0 cut a stake; the largest stake reported was 14.98% on Oct 26.

From the 2025 annual report

Staff: 149 (122 men, 27 women), of whom 144 on fixed-term contracts. Total pay for the year: ₩9.1B. Directors and auditors: 5, paid ₩688M in total.

No cash dividend was paid for 2025.

Largest shareholder

박종훈 holds 19.26%; with 4 related parties the group holds 19.92% of common shares at year end (from 21.53% at the start of the year).

Auditor: 대주회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

1 new supply contract worth 10% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary

5%+ holder reports